Bryan Johnson Longevity Hypothesized Full Protocol

Who Is Bryan Johnson and What Is Blueprint?

Bryan Johnson is a 47-year-old entrepreneur who sold Braintree/Venmo to PayPal for $800 million in 2013. He now funds and subjects himself to what he calls the Blueprint protocol, a self-experiment in biological age reversal. Blueprint is simultaneously a personal health project and a commercial brand, and Johnson publishes most of his interventions openly on blueprint.bryanjohnson.com and in peer-reviewed correspondence.

His stated goal is to achieve "the body of an 18-year-old," measured by validated biological-age clocks and organ-specific benchmarks rather than appearance alone. The experiment is clinically supervised, with a reported team of more than 30 physicians and specialists.

Why This Protocol Matters Clinically

Longevity medicine lacks large randomized controlled trials for most interventions Johnson uses. Rapamycin, metformin, and acarbose each have evidence bases in specific disease populations, but their use in healthy, non-diabetic adults for lifespan extension remains investigational. The TAME trial (Targeting Aging with Metformin, NCT03309007) is the first properly powered RCT examining metformin's effect on aging outcomes in humans, with results expected in the late 2020s [1].

Johnson's self-experiment is therefore a case study, not a clinical recommendation. His openness about outcomes, however, gives clinicians and researchers a rare, densely documented data point.

The Blueprint Data-Transparency Model

Johnson publishes monthly measurement updates, including epigenetic age scores from Horvath-clock-based tests, organ-specific functional assessments, and continuous wearable data. A 2023 paper co-authored by Johnson and colleagues in a preprint described measurable reductions in multiple aging biomarkers [2]. That level of documentation distinguishes Blueprint from most celebrity wellness claims.

Hypothesized Prescription Medications

Johnson publicly names three prescription drugs in interviews, his website, and social media. A fourth, low-dose lithium, sits in a gray zone between supplement and prescription depending on the formulation. Where doses are inferred from context rather than directly stated, this article labels them as [inferred].

Rapamycin (Sirolimus)

Rapamycin is an mTOR inhibitor originally approved by the FDA for organ-transplant rejection prophylaxis and certain rare tumors [3]. In animal models, intermittent rapamycin extended median lifespan in mice by 9 to 14% even when started at the human equivalent of age 60, a finding from the NIA Interventions Testing Program [4].

Johnson has stated publicly that he takes rapamycin on an intermittent schedule. The dose most commonly discussed in longevity circles (and referenced in physician-authored commentary by Dr. Peter Attia and others) is 5 to 10 mg once weekly. [inferred: Johnson's exact dose is not confirmed; 6 mg/week is a commonly cited figure in his public system.]

The principal concern with rapamycin is immune suppression. Weekly low-dose administration appears to produce a more favorable risk profile than daily dosing, based on a 2014 study in older adults showing that the rapalog RAD001 at 0.5 mg daily or 5 mg weekly improved influenza vaccine response by approximately 20%, a proxy for immune function rather than suppression [5].

Metformin

Metformin is an FDA-approved biguanide for type 2 diabetes, but Johnson is not diabetic. He uses it for its proposed longevity effects, which include AMPK activation, mTOR inhibition combination with rapamycin, and reduction of all-cause mortality signals seen in observational studies [6].

The TAME trial (NCT03309007) is enrolling 3,000 adults aged 65 to 79 without diabetes to test whether 1,500 mg/day metformin extended release reduces a composite aging outcome versus placebo [1]. Johnson reportedly takes 1,500 to 2,000 mg/day. [inferred: 1,500 mg is the figure most consistent with his public statements and the TAME trial dose.]

One caveat: a 2021 study in Aging Cell (N=30) found that metformin blunted the mitochondrial adaptations to resistance exercise training [7]. Johnson is an avid resistance trainer. Whether this trade-off is clinically meaningful at his training volume is unresolved.

Acarbose

Acarbose is an alpha-glucosidase inhibitor approved for type 2 diabetes. It slows carbohydrate absorption in the small intestine, blunting post-meal glucose spikes without raising insulin. In the NIA Interventions Testing Program, acarbose extended median lifespan in male mice by 22% and female mice by 5% [8].

Johnson discloses using acarbose alongside his continuous glucose monitor (CGM) to keep post-meal glucose excursions below 30 mg/dL. [inferred: dose likely 25 to 50 mg with meals, consistent with the low end of the approved 25 to 100 mg range.]

Low-Dose Lithium

Lithium orotate at doses of 1 to 5 mg/day (far below psychiatric doses of 300 to 1,200 mg/day lithium carbonate) is included in Johnson's published supplement list. Epidemiological data from a 2017 meta-analysis of 18 studies found that higher regional lithium levels in drinking water correlated with lower all-cause mortality and reduced suicide rates [9]. The mechanism proposed involves GSK-3 beta inhibition and neuroprotection. At 1 mg/day, this functions more as a micronutrient than a psychiatric drug.

The Supplement Stack: Publicly Documented Components

Johnson's supplement regimen runs to more than 50 distinct compounds. The following table covers the most clinically significant, with evidence grades based on available human data.

Longevity and Cellular Aging Targets

NMN (Nicotinamide Mononucleotide), 1 to 2 g/day. NMN is an NAD+ precursor. A 2023 randomized, double-blind trial (N=80) found that 300 mg/day NMN over 60 days significantly increased blood NAD+ levels and improved muscle insulin sensitivity in prediabetic postmenopausal women [10]. Johnson uses higher doses. Whether supraphysiologic NAD+ repletion extends human lifespan is unknown.

Resveratrol, 1 g/day. Resveratrol activates sirtuins (particularly SIRT1) and mimics some caloric restriction signaling. Human bioavailability is poor. A Cochrane systematic review found no consistent benefit on cardiovascular or metabolic endpoints in healthy adults at doses up to 1 g/day [11]. Johnson includes it but its contribution to his outcomes is the hardest to attribute.

Fisetin, 20 mg/kg body weight, two days per month. Fisetin is a flavonoid with senolytic properties, meaning it selectively clears senescent cells. A Mayo Clinic preclinical study in aged mice showed fisetin reduced senescent cell burden and improved physical function [12]. Human trials are underway (NCT03430037) but results are not yet published at scale.

Spermidine, 1 to 2 mg/day. Spermidine induces autophagy. A 2021 randomized trial (N=100) found that 3 months of spermidine supplementation (0.9 mg/day) improved memory performance in older adults with subjective cognitive decline versus placebo [13].

Cardiovascular and Metabolic Support

EPA/DHA (omega-3 fatty acids), 3 to 4 g/day. The REDUCE-IT trial (N=8,179) found that icosapentaenoic acid (EPA) 4 g/day reduced cardiovascular events by 25% versus placebo in statin-treated patients with elevated triglycerides [14]. Johnson's dose falls within this range, though he does not have the cardiovascular risk profile of REDUCE-IT participants.

Vitamin D3, 2,000 to 4,000 IU/day, with vitamin K2. Johnson co-administers K2 (MK-7 form) to direct calcium toward bone rather than vasculature. The VITAL trial (N=25,871) found that vitamin D3 2,000 IU/day did not reduce major cardiovascular events or cancer incidence in the general population [15], though post-hoc analyses suggested benefit in participants with low baseline vitamin D and lower BMI.

Lycopene, 10 mg/day. Lycopene is a carotenoid antioxidant. A meta-analysis of 21 prospective studies found that higher lycopene intake was associated with a 17% lower risk of cardiovascular disease [16]. Johnson includes it as part of his cardiovascular risk reduction stack.

Bone and Musculoskeletal

Calcium alpha-ketoglutarate (CaAKG), 1 g/day. AKG is a TCA cycle intermediate with proposed effects on biological aging. A 2021 mouse study published in Cell Metabolism found that CaAKG supplementation extended median lifespan by 12% and healthspan markers improved more substantially [17]. A human trial is ongoing. Johnson is an early adopter here.

Vitamin K2 (MK-7), 600 mcg/day. As noted above, K2 carboxylates osteocalcin and matrix Gla protein, directing calcium to bone and away from arterial walls. Observational data from the Rotterdam Study found that high menaquinone intake was associated with a 57% lower risk of aortic calcification and a 52% lower risk of coronary heart disease mortality [18].

Cognitive and Neurological

Ashwagandha (KSM-66 extract), 600 mg/day. A 2019 randomized trial (N=60) found that KSM-66 ashwagandha 600 mg/day over 8 weeks significantly reduced cortisol and stress scores versus placebo [19]. Johnson discloses this for stress modulation, which he tracks via cortisol testing.

Lion's Mane Mushroom (Hericium erinaceus), 1 g/day. A 2023 randomized trial (N=41) found that 1.8 g/day lion's mane for 12 weeks improved cognitive performance on processing speed tasks versus placebo in healthy adults aged 18 to 45 [20]. Johnson cites cognitive longevity as a primary target alongside physical aging.

Diet Protocol: The Blueprint Meal Plan

Johnson eats one main meal per day (a modified form of time-restricted eating) and consumes all calories within a roughly 6-hour window, finishing by approximately 11 AM. His daily intake sits at approximately 1,977 kcal, entirely plant-based.

Macronutrient Targets

Protein intake is approximately 130 g/day, achieved through combinations of hemp seeds, lentils, and plant-based protein supplementation. This aligns with recommendations from a 2022 position statement by the International Society of Sports Nutrition, which supports 1.6 to 2.2 g/kg/day for muscle retention during caloric restriction [21].

Fiber intake exceeds 70 g/day, substantially above the 38 g/day Adequate Intake set by the National Academies [22]. The Blueprint "Green Giant" smoothie alone contains approximately 50 g of fiber from ingredients including broccoli, cauliflower, and flaxseed.

Post-Meal Glucose Management

Johnson uses a CGM (reported as Dexcom G7 or equivalent) to monitor post-meal glucose response and targets glucose excursions below 30 mg/dL. The American Diabetes Association Standards of Care define post-meal glucose below 180 mg/dL as acceptable for diabetic patients [23], meaning Johnson holds himself to a considerably stricter standard without having diabetes.

Exercise Protocol

Johnson reports 1 hour of structured exercise daily, 7 days per week, using 25 distinct movement protocols that cycle through resistance training, cardiovascular conditioning, and flexibility work. His reported VO2 max of 53.8 mL/kg/min places him in the top 1.5% for men aged 40 to 44, per normative data published by the American College of Sports Medicine [24].

Resistance Training Focus

Johnson trains with a high-frequency, moderate-load model, prioritizing tendon and ligament integrity alongside muscle mass. Grip strength is one of his tracked biomarkers: a 2018 Lancet study of 139,691 participants across 17 countries found that grip strength was a stronger predictor of cardiovascular mortality than systolic blood pressure [25].

Recovery Metrics

Recovery is monitored via heart rate variability (HRV), resting heart rate, and sleep staging. Johnson reports sleeping at 8:30 PM, targeting 8 hours 10 minutes in bed. A 2019 JAMA Internal Medicine study (N=833,682) found a J-shaped relationship between sleep duration and all-cause mortality, with optimal duration between 7 and 9 hours [26].

Biomarker Monitoring Stack

Johnson tests approximately 100 biomarkers on a quarterly basis. Key targets include:

• LDL-C: below 60 mg/dL (lower than the 70 mg/dL threshold for very high cardiovascular risk per AHA/ACC guidelines [27])
• HbA1c: below 5.0% (normal reference range is below 5.7%)
• Testosterone: mid-range physiologic for a 40s male
• IGF-1: intentionally suppressed through caloric restriction and rapamycin
• Epigenetic age (Horvath clock, PhenoAge): reported as 5 to 10 years below chronological age

The Horvath methylation clock, described in the original 2013 Genome Biology paper, correlates DNA methylation patterns across 353 CpG sites with biological aging across multiple tissue types [28]. Johnson uses this clock and its successors (GrimAge, PhenoAge) as primary outcome measures.

Therapies With Weaker or No Evidence Basis

Plasma Exchange and Young Plasma

Johnson reportedly explored young plasma infusions (parabiosis-inspired). The FDA issued a safety communication in 2019 warning that young donor plasma infusions have no proven clinical benefit and potential harms for conditions including aging [29]. Johnson has publicly stated he paused this intervention after the FDA communication and mixed results in his own tracking.

Testosterone Optimization

Johnson does not use exogenous testosterone by his own account, preferring to optimize endogenous levels through sleep, diet, and resistance training. This is consistent with evidence that sleep restriction reduces testosterone: a 2011 JAMA study (N=10) found that restricting healthy young men to 5 hours of sleep per night for 1 week reduced daytime testosterone levels by 10 to 15% [30].

Risk Profile: What Johnson's Protocol Gets Right and Wrong

The following framework reflects the HealthRX medical team's assessment of Blueprint interventions, stratified by evidence quality and risk level. This framework was developed for editorial use by our reviewing physicians and does not constitute individualized medical advice.

Tier 1 (evidence-supported, low risk at stated doses): Vitamin D3 with K2, EPA/DHA omega-3s, resistance exercise, sleep optimization, fiber-dense diet, CGM-guided glucose management, HRV monitoring.

Tier 2 (promising preclinical or early human data, moderate risk): Metformin in non-diabetic adults (TAME trial ongoing), NMN/NR for NAD+ repletion, spermidine, CaAKG, lion's mane mushroom.

Tier 3 (investigational, requires physician supervision, non-trivial risk): Rapamycin (immune suppression, wound healing impairment, lipid changes), acarbose (GI side effects, drug interactions), fisetin at senolytic doses, low-dose lithium (requires monitoring).

Tier 4 (insufficient evidence or active safety signals): Young plasma infusions (FDA safety communication 2019 [29]), supraphysiologic hormone regimens without documented deficiency.

The central clinical tension in Blueprint is that Tier 3 interventions produce the most dramatic biomarker changes in Johnson's tracking data, but they also carry the highest risk of harm in individuals without Johnson's level of medical supervision.

What Physicians Should Know About Patients Requesting Blueprint-Style Protocols

Patients presenting with interest in Bryan Johnson's protocol are typically health-optimizing adults, not acutely ill. The requests most likely to reach a prescribing physician are for rapamycin, metformin, and acarbose off-label.

Off-Label Rapamycin: Key Prescribing Considerations

The Interventions Testing Program data in mice [4] and the rapalog immune study [5] are the strongest human-adjacent evidence for low-dose intermittent rapamycin in aging. Before prescribing, clinicians should check baseline lipids (rapamycin causes dyslipidemia), CBC, and renal function. Drug interactions with CYP3A4 inhibitors are significant; a 2020 review in the Journal of the American Geriatrics Society outlined a practical clinical framework for rapamycin use in older adults [31].

Metformin in Non-Diabetic Adults

Per the American Diabetes Association 2024 Standards of Care, metformin may be considered for individuals with prediabetes, particularly those under 60 with BMI above 35, or women with prior gestational diabetes [23]. Use in fully euglycemic individuals remains outside approved indications. B12 monitoring is mandatory with long-term metformin use, as depletion affects 6 to 30% of chronic users [23].

The Lab Baseline Before Any Protocol

The HealthRX medical team recommends, at minimum, a baseline comprehensive metabolic panel, CBC, HbA1c, fasting lipids, hsCRP, testosterone, DHEA-S, IGF-1, vitamin D 25-OH, and B12 before initiating any Blueprint-adjacent protocol. Quarterly monitoring is appropriate for patients on rapamycin or metformin off-label.